CAS 63527-52-6|cefotaxime
| Common Name | cefotaxime | ||
|---|---|---|---|
| CAS Number | 63527-52-6 | Molecular Weight | 455.466 |
| Density | 1.8±0.1 g/cm3 | Boiling Point | / |
| Molecular Formula | C16H17N5O7S2 | Melting Point | 162-163℃ |
| MSDS | / | Flash Point | / |
Names
| Name | cefotaxime |
|---|---|
| Synonym | More Synonyms |
cefotaxime BiologicalActivity
| Description | Cefotaxime, a third-generation cephalosporin antibiotic, possesses broad-spectrum antibiotic activity against numerous Gram-positive and Gram-negative bacteria[1][2][3][4]. |
|---|---|
| Related Catalog | Research Areas >>InfectionResearch Areas >>Inflammation/ImmunologySignaling Pathways >>Anti-infection >>Bacterial |
| In Vitro | Cefotaxime exhibits an MIC of 0.0625 mg/L for V. vulnificus CMCP6[4]. |
| In Vivo | The combination of ciprofloxacin and cefotaxime is more effective in clearing V. vulnificus in vivo than previously used regimens[4]. Animal Model: Female, specific pathogen free, 8-week-old BALB/c mice[4]. Dosage: 30 mg/kg. Administration: IP every 6 h. Result: The viable bacterial counts in liver were lower in mice treated with cefotaxime-plus-ciprofloxacin than in those treated with cefotaxime alone (P<0.001 at 24 h and 48 h, each). |
| References | [1]. Hee-Chang Jang, et al. In vivo efficacy of the combination of ciprofloxacin and cefotaxime against Vibrio vulnificus sepsis. PLoS One. 2014 Jun 30;9(6):e101118. [2]. Woodfield JC, et al. A comparison of the prophylactic efficacy of ceftriaxone and cefotaxime in abdominal surgery. Am J Surg. 2003 Jan;185(1):45-9. [3]. Scholz H, et al. Prospective comparison of ceftriaxone and cefotaxime for the short-term treatment of bacterial meningitis in children. Chemotherapy. 1998 Mar-Apr;44(2):142-7. [4]. Gums JG, et al. Differences between ceftriaxone and cefotaxime: microbiological inconsistencies. Ann Pharmacother. 2008 Jan;42(1):71-9. |
Chemical & Physical Properties
| Density | 1.8±0.1 g/cm3 |
|---|---|
| Melting Point | 162-163℃ |
| Molecular Formula | C16H17N5O7S2 |
| Molecular Weight | 455.466 |
| Exact Mass | 455.056946 |
| PSA | 227.05000 |
| LogP | 1.20 |
| Index of Refraction | 1.779 |
| InChIKey | GPRBEKHLDVQUJE-FMXWCYLFSA-N |
| SMILES | CON=C(C(=O)NC1C(=O)N2C(C(=O)O)=C(COC(C)=O)CSC12)c1csc(N)n1 |
| Storage condition | 2-8℃ |
Safety Information
| HS Code | 3003201100 |
|---|
Customs
| HS Code | 3003201100 |
|---|
Articles27
More Articles| Effects of decontamination of the digestive tract and oropharynx in intensive care unit patients on 1-year survival. Am. J. Respir. Crit. Care Med. 188(1) , 117-20, (2013) | |
| National surveillance study on carbapenem non-susceptible Klebsiella pneumoniae in Taiwan: the emergence and rapid dissemination of KPC-2 carbapenemase. PLoS ONE 8(7) , e69428, (2013) The global spread and increasing incidence of carbapenem non-susceptible Klebsiella pneumoniae (CnSKP) has made its treatment difficult, increasing the mortality. To establish nationwide data on CnSKP... | |
| Synthesis, characterization, and antimicrobial activity of poly(acrylonitrile-co-methyl methacrylate) with silver nanoparticles. Appl. Biochem. Biotechnol. 171(3) , 643-54, (2013) Nanotechnology is expected to open some new aspects to fight and prevent diseases using atomic-scale tailoring of materials. The main aim of this study is to biosynthesize silver nanoparticles (AgNPs)... |
Synonyms
| 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 3-[(acetyloxy)methyl]-7-[[2-(2-amino-4-thiazolyl)-2-(methoxyimino)acetyl]amino]-8-oxo-, (6R,7R)- |
| Cefotaxime |
| (6R,7R)-3-(Acetoxymethyl)-7-{[(2-amino-1,3-thiazol-4-yl)(methoxyimino)acetyl]amino}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid |
| Zariviz |
| Cefabol |
| Cefotaxima acid |
| EINECS 264-299-1 |
| Cephotaxime |
